THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究

• 批准号: 9200920
• 负责人: CAROL E GREEN
• 金额: $ 0.6万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-23 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9200920
• 关键词: Antineoplastic Agents; Cell Culture Techniques; Clinical; Congestive Heart Failure; Cyclic GMP; Diabetes Mellitus; Dose; Evaluation; Immune System Diseases; Neurodegenerative Disorders; Pharmaceutical Preparations; Rodent; cancer cell; preclinical evaluation; preclinical study; research clinical testing

(R,R’)-4’-methoxy-1-napthylfenoterol (MNF) is a candidate anticancer agent developed within IRP, NIA that has demonstrated activity across a number of cancer cell culture lines. Preliminary studies in rodents suggest that the agent may possess anticancer action at tolerable doses and support further evaluation of the agent. There is hence a requirement for larger drug amounts to continue preclinical evaluation of MNF as well as potential clinical evaluation. To support this, Task Order 17 is to synthesize no less than 2 kg of cGMP (clinical grade) MNF material.

（R，R '）-4'-甲氧基-1-萘基非诺特罗（MNF）是在IRP，NIA中开发的候选抗癌剂，其已在许多癌细胞培养系中显示出活性。在啮齿动物中的初步研究表明，该药物在可耐受剂量下可能具有抗癌作用，并支持对该药物进行进一步评价。因此，需要更大的药物量来继续进行MNF的临床前评价以及潜在的临床评价。为了支持这一点，任务指令17是合成不少于2 kg的cGMP（临床级）MNF材料。